The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Evaluation of Striatal Dopamine Transporter Density using $[^{123}I]-{\beta}-CIT$ SPECT in Schizophrenic Patients Treated with Olanzapine: Pilot study

정신분열병 환자에서 Olanzapine 사용 전후의 $[^{123}I]-{\beta}-CIT$ SPECT를 이용한 Dopamine Transporter 변화: 준비조사

  • 김철응 (인하대학교 의과대학 정신과학교실) ;
  • 문혜원 (인하대학교 의과대학 정신과학교실) ;
  • 최원식 (인하대학교 의과대학 핵의학과) ;
  • 김창호 (인하대학교 의과대학 핵의학과) ;
  • 지대윤 (인하대학교 의과대학 화학과)
  • Published : 2002.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This pilot study was performed to understand the pharmacological effect of olanzapine, an atypical antipsychotic agent, on dopamine transporter in schizophrenic patients. Materials and Methods: Six patients (3 male, 3 female) with schizophrenia, who had not taken any psychotropic drugs for at least four weeks, were studied. Nuclear imaging using $[^{123}I]-{\beta}-CIT$ SPECT was obtained before and after 4-week treatment with olanzapine. Analysis of ROI on the striatum, caudate nucleus, and putamen was performed. Results: Post-treatment uptake was significantly increased in all the ROIs compared with pre-treatment uptake. Conclusion: This preliminary study with the small number of schizophrenic patients suggested an increase in uptake of dopamine transporter in the striatum, caudate nucleus, and putamen after 4-week treatment with olanzapine, which warrants a large-scaled controlled study to confirm the current findings.

목적: 정신분열병의 병태생리와 이미 임상적인 효과와 안전성이 확인된 비정형항정신병약물의 하나인 올란자핀의 작용기전 중 도파민전달체에 대한 효과를 구명하고자 본 연구를 고안했다. 대상 및 방법: 최소 4주 이상 항정신병약물을 사용하지 않았고 DSM-IV진단기준을 만족시키는 정신분열병 환자 6명(남 3, 여 3)에게 본 연구의 목적을 설명한 후 동의를 얻고 올란자핀 사용 전, 사용 4주 후 2회 $[^{123}I]-{\beta}-CIT$ SPECT영상을 얻었다. 얻은 영상에서 선조체/후두엽 비율을 측정했고 미상/피각으로 나누어 약물 사용 전 후를 비교분석 했다. 결과: 선조체 및 미상/피각 전부위의 $[^{123}I]-{\beta}-CIT$ 결합율은 올란자핀 사용 4주후 사용 전에 비해 의미있는 증가를 보였다(p<0.05). 결론: 본 연구결과는 올란자핀이 도파민전달계 중 도파민 운반체에 변화를 보임을 시사하고 있으나 확증을 위해서는 더 많은 환자와 정상인을 대상으로 한 비교 연구가 필요하다고 생각된다.

Keywords

References

  1. Davis KL, Kahn RS, Ko G, Davidson M.Dopamine in schizophrenia: a review and reconceptualization.Am J Psychiatry 1991;148: 147486.
  2. Lieberman JA, Kane JM, A1vir J. Provocativetests with psychostimulant drugs in schizophrenia.Psychopharmacology 1987;91:415-33.
  3. Laruelle M, Abi-Dargham A, Gil R, Erdos J,D'Souza CD, Zoghbi SS, et al. SPECT measurementsof dopamine transporters in schizophrenia(abstr). J Nucl Med 1996; (Suppl 37):33P.
  4. Laruelle M, Abi-Dargham A, van Dyck CH, GilR, De Souza CD, Erdos J, et al. Single photonemission computerized tomography imaging ofamphetamine-induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad SciUSA 1996b;93:9235-40.
  5. Laruelle M, Abi-Dargham A, Gil R, Kegeles L,Innis R. Increased dopamine transmission inschizophrenia: relationship to illness phases. BiolPsychiatry 1999;46:56-72.
  6. Reith J, Benkelfat C, Sherwin A, Yasuhara Y,Kuwabara H, Andermann F, et al. Elevated dopadecarboxylase activity in living brain of patientswith psychosis. Proc Natl Acad Sci USA1994;91:11651-4.
  7. Hietala J, Syvalahti E, Vuorio K, RakkolainenV, Bergman J, Haaparanta M, et al. Presynapticdopamine function in striatum of neurolepticnaive schizophrenic patients. Lancet 1995;346:lBO-I.
  8. Hantraye P, Brownell AL, Elmaleh D, SpealmanRD, Wullner D, Brownell GL, et al. Dopaminefiber detection by [l1C]-CFT and PET in aprimate model of parkinsonism. Neuroreport1992;3:265-8.
  9. Jaber M, Jones S, Giros B, Caron MG. Thedopamine transporter: A crucial componentregulating dopamine transmission. Movement Dis1997;12:629-33.
  10. Chinaglia G, Alvarez FJ, Probst A, Palacios JM.Mesostriatal and mesolimbic dopamine dopamineuptake binding sites are reduced in Parkinson'sdisease and progressive supranuclear palsy: Aquantitative autoradiographic study using eH]mazindol. Neuroscience 1992;49:317-27.
  11. Czudek C, Reynolds GP. eH]GBR 12935binding to the dopamine uptake site in postmortembrain tissue in schizophrenia. J Neural Transm 1989;77:227-30.
  12. Knable MB, Hyde TM, Herman MM, CarterJM, Bigelow L, Kleinman JE. Quantitativeautoradiography of dopamine Dl receptors, D2receptors, and dopamine uptake sites in postmortemstriatal specimens from schizophrenicpatients. BioI Psychiatry 1994;36: 827-35.
  13. Pearce RK, Seeman P, Jellinger K, TourtellotteWW. Dopamine uptake sites and dopaminereceptors in Parkinson's disease and schizophrenia.Eur Neurol 1990;30(Suppl 1): 9-14.
  14. Van Dyck CH, Seibyl JP, Malison RT, LaruelleM, Wallace E, Zoghbi SS, et al. Age-relateddecline in striatal dopamine transporter bindingwith iodine-123-beta- CIT SPECT. J Nucl Med1995;36:1175-81.
  15. Volkow ND, Fowler JS, Wang GJ, Logan J,Schlyer D, McGregor R, et al. Decreaseddopamine transporters with age in health humansubjects. Ann Neurol 1994;36:237-9.
  16. Lieberman JA, Sheitman BB, Kinon BJ.Neurochemical sensitization in the pathophysiologyof schizophrenia: Deficits and dysfunctionin neuronal regulation and plasticity. Neuropsychopharmacology1997;17:205-29.
  17. Booij J, Hemelaar JM, Speelman JD, de BruinK, Janssen AM, van Royen EA. One-day protocolfor imaging of the nigrostriatal dopaminergicpathway in Parkinson's disease by C23I]FP CITSPECT. J Nucl Med 1999;40:753-61.
  18. Laruelle M, Abi-Dargham A, van Dyck C, GilR, D'Souza DC, Krystal J, et al. Dopamine andserotonin transporters in patients with schizophrenia:An imaging study with C23I]-CIT. BiolPsychiatry 2000;47:371-9.
  19. Farde L, Nordstrom AL, Wiesel FA, Pauli S,Halldin C, Sedvall G. Positron emission tomographicanalysis of central DI and D2 dopaminereceptor occupancy in patients treated withclassical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538- 44.
  20. Nordstrom AL, Farde L, Wiesel FA, ForslundK, Pauli S, Halldin C, et al. Central D2dopamine receptor occupancy in relation toantipsychotic drug effects: A double- blind PETstudy of schizophrenic patients. Bioi Psychiatry1993;33:227-35.
  21. Schroder J, Silvestri S, Bubeck B, Karr M,Demisch S, Scherrer S, et al. D2 dopaminereceptor up-regulation, treatment response,neurological soft signs, and extrapyramidal sideeffects in schizophrenia: A follow-up study with123H odobenzamide single photon emission computedtomography in the drug-naive state andafter neuroleptic treatment. Bioi Psychiatry1998;43:660-5.
  22. Lavalaye J, Linszen DH, Booij J, DingemansPMAJ, Reneman L, Habraken JBA, et al.Dopamine transporter density inn young patientswith schizophrenia assessed with e2) ]FP-CITSPECT. Schizophr Res 2001;47: 59-67.
  23. Burt DR, Creese I, Snyder SH. Antischizophrenicdrugs: Chronic treatment levates dopamine receptorbinding in brain. Science 1976;196:326-7.
  24. Clow A, Theodorou A, Jenner P, Marsden CD.Changes in rat striatal dopamine turnover andreceptor activity during on years neurolepticadministration. Eur J Pharmacology 1980;63:135-44.
  25. Jeon BS, Kim JM, Jeong JM, Kim KM, ChangYS, Lee DS, et al. Dopamine transporterimaging with e23I]_f! -CIT demonstrates presynapticigrostriatal dopaminergic damage inWilson's disease. J Neurol Neurosurg Psychiatry1998;65:60-4.
  26. Jeon BS, Jeong JM, Park SS, Kim JM, ChangYS, Song HC, et al. Dopamine transporter density measured by C23I]_f! - CIT single photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neural 1998;43:792-800.
  27. Damasio H, Damasio AR. Lesion analysis inneuropsychology. New York: Oxford UniversityPress; 1989. Appendix A.4.
  28. Joyce IN, Lexow N, Bird E, Winokur A.Organization of dopamine Dl and D2 recptors inhuman striatum: receptor autoradiographic studiesin Huntington's disease and schizophrenia.Synapse 1998;2:546-57.
  29. Bannon MJ, Granneman JG, Kapatos G. Thedopamine transporter: potential involvement inneuropsychiatric disorders, In: Bloom FE, KupferDJ, editors. Psychopharmacology: The FourthGeneration of Progress. New York: RavenPress; 1995. p. 179-88.
  30. Tatsch KR, Scherer J, Linke R, Kerner M, HahnK. Decrease of dopamine transporter binding inneuroleptic free schizophrenic patients assessedwith IPT-SPECT(abstr). J Nue! Med 1999;40Suppl:31P.
  31. Wong DE In vivo imaging of D2 dopaminereceptors in schizophrenia. Arch Gen Psychiatry2002;59:31-4.
  32. Kim SE, Lee WY, Chi DY, Choe YS, Lee KH,Choi Y, et al. SPECT imaging of dopaminetransporter with C23I]-CIT : A potential clinicaltool in Parkinson's disease. Korean J Nucl Med1996;30:19-34.
  33. Kim SE, Lee WY, Choe YS, Kim KM, Chi DY,Kim BT. Assessment of Parkinson's diseaseseverity with C23I]-CIT and single photon emissioncomputed tomography. J Korean NeurologicalAss 1997;15:109-20.